Stealth BioTherapeutics Granted Pre-NDA Meeting for Elamipretide as a Potential Treatment for Barth Syndrome

Type B meeting scheduled with FDA Division of Cardiology and Nephrology

Company plans to discuss new clinical data that may inform a potential NDA submission

Read more at prnewswire.com